Nanobiotix(US:NBTX)2026-03-31 20:27Financial Performance - The company has incurred losses totaling €400.8 million since inception, with a net loss of €24.0 million for the year ended December 31, 2025[101]. - As of December 31, 2025, the company had cash and cash equivalents of €52.8 million[101]. - The company anticipates ongoing significant losses for the foreseeable future due to its focus on research and development[96]. - The company has not yet established a source of revenues sufficient to cover its operating costs[103]. - The company may encounter difficulties in raising additional funding, which could adversely affect its business and financial position[104]. Development and Clinical Trials - The company expects to continue incurring significant expenses related to the development and manufacturing of nanotechnology product candidates and conducting clinical studies[102]. - The company’s product candidates are in various phases of development, with a high rate of attrition expected[112]. - Clinical trials for product candidates, including JNJ-1900 (NBTXR3), may encounter substantial delays or fail to demonstrate safety and efficacy[120]. - Patient enrollment challenges could delay or prevent clinical studies, impacting the timeline for regulatory approval[133]. - The company faces potential delays in patient enrollment for clinical trials, which could increase costs and affect the timing of analyses and outcomes[137]. - Undesirable side effects from product candidates may halt clinical development, delay regulatory approval, or limit commercial potential[138]. - Limited clinical trial applications may reveal high incidence of side effects, impacting the development of product candidates[139]. Strategic Partnerships and Licensing - The company relies on its strategic licensee, Janssen, for the clinical development and commercialization of its lead product candidate JNJ-1900 (NBTXR3)[92]. - The global exclusive licensing agreement with Janssen is critical, as future payments from this agreement are expected to contribute significantly to revenue[159]. - The company transferred the sponsorship of the NANORAY-312 clinical trial to JJEI, increasing reliance on Janssen for oversight[160]. - The company relies on third-party partners for the development and commercialization of JNJ-1900 (NBTXR3), increasing operational risks[157]. - The company may face significant disruptions if Janssen terminates the licensing agreements, impacting expected revenue and operational stability[163]. Regulatory and Compliance Risks - The approval processes for product candidates, such as JNJ-1900 (NBTXR3), are lengthy and costly, with no guarantee of success[212]. - Regulatory changes could significantly increase costs and complexity in drug development, impacting the economic value of product candidates[211]. - Ongoing regulatory requirements will apply even after obtaining marketing authorization, affecting manufacturing, labeling, and post-market safety[217]. - Compliance with healthcare laws is essential to avoid significant penalties and reputational harm, impacting future earnings[221]. - The company is subject to numerous environmental, health, and safety laws, and failure to comply could result in substantial costs and impair research and development efforts[191]. Intellectual Property Risks - The company's competitive position may decline if it fails to adequately protect its intellectual property rights, including patents and trade secrets[237]. - Patent protection is uncertain due to potential challenges from third parties and the lengthy process of obtaining patents, which may affect the commercialization of product candidates[238]. - The lifespan of patents is limited, with issued patents and applications expiring between 2029 and 2045, potentially impacting the company's competitive advantage[250]. - The company may not seek patent protection in all jurisdictions, limiting its ability to enforce intellectual property rights globally[252]. - The company’s success depends on its ability to operate without infringing on third-party intellectual property rights, which could lead to costly litigation or licensing fees[263]. Operational and Management Risks - The company expects its employee base to continue to grow as it manages development and expansion, which includes operating manufacturing facilities and commercializing product candidates[181]. - The management identified no material weaknesses in internal control over financial reporting as of December 31, 2025, but future weaknesses could limit the ability to prevent or detect misstatements[196]. - The company relies heavily on key management personnel, and losing them could have a material adverse effect on its operations[272]. - Attracting and retaining qualified personnel is critical, and failure to do so could negatively impact the company’s ability to develop its product candidates[273]. Market and Competitive Environment - The company faces substantial competition in the biotechnology and oncology industries from companies with greater resources and experience[98]. - Pricing pressures are expected to continue and may increase, making it difficult for the company to sell future products at acceptable prices[233]. - Political and legislative uncertainty may harm the company's ability to market products and generate revenues, potentially increasing compliance and operating expenses[232]. - Cost-containment measures by governments and payors may adversely affect the company's ability to set fair prices for its products[226]. Cybersecurity and Data Privacy Risks - Cybersecurity threats, including ransomware attacks, pose significant risks to the company's information technology systems and could disrupt operations and clinical trials[198]. - Data privacy regulations, including GDPR and HIPAA, impose requirements on the collection and use of personally identifiable information, and non-compliance could adversely affect the company's operations and financial condition[203]. - The company faces potential civil and criminal penalties if it fails to comply with applicable privacy laws, including GDPR and HIPAA[206].